MedTrace Logo

First-time Ablation of Atrial Fibrillation Registry

NCT06381245 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2024-08-13

No results posted yet for this study

Summary

Atrial fibrillation (AF) is a prevalent cardiac arrhythmia affecting millions globally, with projections indicating a doubling of cases by 2050. AF is linked to heightened cardiovascular risks like stroke and increased healthcare costs. Ablation, targeting the arrhythmia substrate, is a method to manage AF, yet recurrence rates remain high (20-45% in the first year). Studies highlight the impact of comorbidities, AF characteristics, ablation techniques, and myocardial remodeling markers on AF progression and ablation efficacy. However, there's no definitive guidance on selecting these factors for predicting treatment success.

The aim of this study is to investigate predictors of successful AF ablation in the following areas: (a) clinical factors, (b) electrophysiological, (c) electrocardiographic, (d) ultrasound, (e) cardiac anatomy, (f) biomarkers.

Conditions

Interventions

DIAGNOSTIC_TEST

PPG-based remote heart rhythm/rate monitoring

PPG-based remote heart rhythm/rate monitoring

DIAGNOSTIC_TEST

ECG-based remote heart rhythm/rate monitoring

ECG-based remote heart rhythm/rate monitoring

DIAGNOSTIC_TEST

Transthoracic and transesophageal echocardiography examination

Transthoracic and transesophageal echocardiography examination

DIAGNOSTIC_TEST

Liver ultrasound examination

Liver ultrasound examination

DIAGNOSTIC_TEST

Rotational angiography with three-dimensional reconstruction

Rotational angiography with three-dimensional reconstruction

DIAGNOSTIC_TEST

Blood-derived biomarker analysis

Blood-derived biomarker analysis

DIAGNOSTIC_TEST

Mobile health-based spirometry

Mobile health-based spirometry

Sponsors & Collaborators

  • Medical University of Warsaw

    lead OTHER

Principal Investigators

  • Monika Gawałko, MD, PhD · 1st Department of Cardiology, Medical University of Warsaw

  • Paweł Balsam, MD, PhD · 1st Department of Cardiology, Medical University of Warsaw

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2026-03-31
Completion
2026-03-31

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06381245 on ClinicalTrials.gov